ARUP's Laboratory Test Directory
| 0055566: Apolipoprotein E (APOE) 2 Mutations, Cardiovascular Risk |
![[ image for: Patient History For Molecular Genetics]](icon_21.jpg){kind=icon} | Patient History For Molecular Genetics |
| Test Mnemonic: APO E | |
|
Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu Reported: 2-7 days |
| Specimen Required: | |
|
Collect: One 5 mL lavender (EDTA) or pink (K2EDTA). (Min: 3 mL) Also acceptable: yellow (ACD Solution A), lt. blue (sodium citrate), or green (sodium or lithium heparin).
Transport: 5 mL whole blood at 2-8°C. (Min: 3 mL) Pediatric Collection/Transport: 1 mL whole blood at 2-8°C. Unacceptable Conditions: Serum or frozen whole blood. Severely hemolyzed specimens. Stability: Ambient: 3 days; Refrigerated: 1 week; Frozen: Unacceptable |
|
| Reference Interval: |
| Homozygous apo e3 (e3/e3): This genotype is the most common (normal) genotype. |
| Interpretive Data: | |
|
Background Information for Apolipoprotein E (APOE) 2 Mutations, Cardiovascular Risk Characteristics: Hyperlipoproteinemia III (HPL III) is characterized by increased cholesterol and triglyceride levels, presence of B-VLDL, xanthomas, and premature vascular disease including coronary heart disease (CHD) and peripheral artery disease. Incidence of HPL III: Approximately 1 in 5,000. Inheritance: Autosomal recessive. Penetrance: 1 to 5 percent of individuals homozygous for the E2 allele and 26 percent of those heterozygous for both E2 and familial hypercholesterolemia will develop symptoms. Cause: The E2 isoform binds the lipoprotein receptors with only 2 percent of the affinity of E3 and E4 resulting in impaired clearance of chylomicron and VLDL remnants and increased plasma cholesterol and triglyceride levels. Mutations tested: E2, E3 (normal) and E4 alleles of the apolipoprotein E gene. Clinical Sensitivity: About 5 percent of individuals with premature CHD are homozygous for E2. Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring using hybridization probes. Analytical Sensitivity and Specificity: 99 percent. Limitations: Rare isoforms of APOE will not be detected. If rare alleles are suspected, phenotyping by isoelectric focusing may be indicated. Rare diagnostic errors can occur due to primer site muations. This test is performed pursuant to an agreement with Roche Molecular Systems, Inc. Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com. Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory. |
| Note: | |
|
This test is for cardiovascular risk assessment only and must not be ordered for assessing Alzheimer disease in a demented patient. Athena Neurosciences, Inc. is the exclusive licensee of U.S. Patent No. 5,508,167 for the Alzheimer risk assessment. This test is not recommended for nonsymptomatic patients under 18 years of age. For a complete description of the Reference Interval, please refer to ARUP's Guide to Clinical Laboratory Testing, which can be found on our Web site at www.aruplab.com. |
| CPT Code(s): | |
|
83890 Isolation; 83898 Amplification; 83896 x2 Nucleic acid probes; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders. |